Full Name
Prof. Kim Linton MBChB, MRCP, PhD
Job Title
Professor of Medical Oncology
Company/Affiliation
The University of Manchester
Speaker Bio
Kim Linton is a Professor of Medical Oncology at the University of Manchester and an Honorary Consultant at The Christie NHS Foundation Trust, one of Europe’s leading cancer centres. She also holds an honorary academic appointment at the University of Liverpool. A recognized leader in lymphoma clinical research, Prof Linton oversees a portfolio of investigator-led and industry-sponsored clinical trials spanning early-phase, late-phase, and real-world studies. She holds senior roles in several national and international trials, including REFRACT, PETReA, RADAR, EPCORE NHL-1, EPCORE FL-1 and FL-2, FOUNDATION UK, BRAMBLE, and UNCOVER PLUS.
Her translational research focuses on the late effects of cancer treatment and biomarker development, and she co-leads the Living With and Beyond Cancer Theme within the National Institute for Health and Care Research NIHR Manchester Biomedical Research Centre. Current projects are evaluating lung cancer screening in Hodgkin lymphoma survivors through the SEARCH study, developing proteomic biomarkers for early detection of anthracycline-induced cardiotoxicity, and applying digital pathology for risk stratification in Follicular and Hodgkin lymphomas.
She is the Immediate Past Chair of the UK Lymphoma Group Low Grade Lymphoma Study Group and was the Scientific Secretary of the European Haematology Association Lymphoma Specialized Working Group until 2025. She chairs the Christie Lymphoma Group and the UK Blood Cancer Biobank Oversight Committee. She is a medical advisor for Lymphoma Action and a standing member of the Cancer Research UK Expert Review Group.
Professor Linton contributes to postgraduate education as Course Co-Lead for the Systemic Therapy Module of the University of Manchester Oncology Masters course. She lectures on the Oxford Lymphoma Management Course, supervises PhD and master's students and provides clinical and educational supervision for oncology trainees.
She is regularly invited to speak at scientific meetings and educational events and contributes to national and international guideline development through roles with NICE, the British Society for Haematology, and the European Hematology Association. She also serves as a clinical expert for technology appraisals and advisory boards.
Professor Linton has authored over 100 peer-reviewed publications. Her most recent work centres on advancing bispecific antibody therapies - particularly epcoritamab and glofitamab - for relapsed or refractory lymphomas, with influential publications in Blood and the British Journal of Haematology shaping emerging treatment standards. She has also contributed high‑impact research on frontline and personalized treatment strategies for follicular lymphoma, groundbreaking therapies for CNS lymphomas such as the
MATRix and MARIETTA regimens and on genomic optimization of Hodgkin lymphoma therapy through
updated BEACOPP regimen.
Her translational research focuses on the late effects of cancer treatment and biomarker development, and she co-leads the Living With and Beyond Cancer Theme within the National Institute for Health and Care Research NIHR Manchester Biomedical Research Centre. Current projects are evaluating lung cancer screening in Hodgkin lymphoma survivors through the SEARCH study, developing proteomic biomarkers for early detection of anthracycline-induced cardiotoxicity, and applying digital pathology for risk stratification in Follicular and Hodgkin lymphomas.
She is the Immediate Past Chair of the UK Lymphoma Group Low Grade Lymphoma Study Group and was the Scientific Secretary of the European Haematology Association Lymphoma Specialized Working Group until 2025. She chairs the Christie Lymphoma Group and the UK Blood Cancer Biobank Oversight Committee. She is a medical advisor for Lymphoma Action and a standing member of the Cancer Research UK Expert Review Group.
Professor Linton contributes to postgraduate education as Course Co-Lead for the Systemic Therapy Module of the University of Manchester Oncology Masters course. She lectures on the Oxford Lymphoma Management Course, supervises PhD and master's students and provides clinical and educational supervision for oncology trainees.
She is regularly invited to speak at scientific meetings and educational events and contributes to national and international guideline development through roles with NICE, the British Society for Haematology, and the European Hematology Association. She also serves as a clinical expert for technology appraisals and advisory boards.
Professor Linton has authored over 100 peer-reviewed publications. Her most recent work centres on advancing bispecific antibody therapies - particularly epcoritamab and glofitamab - for relapsed or refractory lymphomas, with influential publications in Blood and the British Journal of Haematology shaping emerging treatment standards. She has also contributed high‑impact research on frontline and personalized treatment strategies for follicular lymphoma, groundbreaking therapies for CNS lymphomas such as the
MATRix and MARIETTA regimens and on genomic optimization of Hodgkin lymphoma therapy through
updated BEACOPP regimen.
Speaking At
